

COURSE FACULTY, IAS–USA STAFF, BOARD OF DIRECTORS, AND VIRAL HEPATITIS ADVISORY BOARD FINANCIAL RELATIONSHIPS WITH COMMERCIAL ENTITIES

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, course faculty, IAS–USA Board members, Viral Hepatitis Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the previous 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity. The **ACCME defines a commercial interest** as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The **ACCME** does not consider providers of clinical service directly to patients to be **commercial interests** – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.” Below are the financial interests that faculty members of this course have had within the past 12 months as of the date listed. View the [Faculty Financial Disclosure Policy](#).

ATLANTA, GEORGIA—MARCH 29, 2019

Course Chairs	
Jeffrey L. Lennox, MD Professor of Medicine Associate Dean for Clinical Research Emory University Atlanta, Georgia	<i>Dr. Lennox has received research funding to his institution from Bristol-Myers Squibb and ViiV Healthcare and served as a consultant to Gilead Sciences, Inc. (Updated 03/20/19)</i>
Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham, Alabama	<i>Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc, Merck, and ViiV Healthcare. He has also served as a consultant for Gilead Sciences, Inc, Merck, and ViiV Healthcare. (Updated 11/30/18)</i>
Speakers	
Susan Buchbinder, MD Clinical Professor of Medicine and Epidemiology University of California San Francisco Director, Bridge HIV San Francisco Department of Public Health San Francisco, California	<i>Dr Buchbinder has participated in research trials that have received provision of medicines from Gilead Sciences, Inc. (Updated 03/01/19)</i>
Peter Chin-Hong, MD Professor of Medicine University of California San Francisco San Francisco, California	<i>Dr Chin-Hong has received research support from Karius. (Updated 12/07/18)</i>
Jonathan Li, MD, MMSc, FIDSA Assistant Professor of Medicine Brigham and Women's Hospital Harvard Medical School Boston, Massachusetts	<i>Dr Li has served as a consultant to Quest Diagnostics and Jan Biotech. (Updated 03/15/19)</i>
Kenneth E. Sherman, MD, PhD Gould Professor of Medicine University of Cincinnati Cincinnati, Ohio	<i>Dr Sherman has received research grants or contracts awarded to his institution from AbbVie, Gilead Sciences, Inc, Intercept Pharmaceuticals, Inc, MedImmune, and Merck. He has served as an advisory board member or a consultant to Abbott Laboratories, Inovio Pharmaceuticals, and UniQure. He has also served on data safety monitoring boards for Watermark and Medpace. (Updated 03/20/19)</i>
Melanie A. Thompson, MD Principal Investigator AIDS Research Consortium of Atlanta Atlanta, Georgia	<i>Dr Thompson's institution has received grants for research from Bristol-Myers Squibb, CytoDyn, Inc, Frontier Biotechnologies, Gilead Sciences, Inc, GlaxoSmithKline, Merck, and ViiV Healthcare. (Updated 03/15/19)</i>
Kimberly Workowski, MD Professor of Medicine Emory University Atlanta, Georgia	<i>Dr Workowski has received research support from Gilead Sciences, Inc. (Updated 02/28/19)</i>
IAS–USA CME Planner and Reviewer	
Donna M. Jacobsen Executive Director	<i>Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 02/06/19)</i>
IAS–USA Board of Directors	
The nonstaff members of the IAS–USA Board of Directors are not compensated for their roles in governing and overseeing the IAS–USA. Please see https://iasusa.org/about/ias-usa-board-of-directors/ for information about board members and a link to up-to-date financial disclosure information.	
IAS–USA Viral Hepatitis Advisory Board	
The members of the IAS–USA Viral Hepatitis Advisory Board are not compensated for their roles in governing and overseeing the IAS–USA viral hepatitis educational efforts. Please see https://iasusa.org/activities/live-courses/hepatitis-c-virus-courses/viral-hepatitis-advisory-board/ for information about the financial disclosures for the IAS–USA Viral Hepatitis Advisory Board.	